InDex Pharmaceuticals Holding AB Statistics
InDex Pharmaceuticals Holding AB (1NP1) Stock Statistics & Valuation Metrics
Total Valuation
InDex Pharmaceuticals Holding AB has a market cap or net worth of EUR 107.45M. The enterprise value is EUR 1.15B.
- Market Cap
- EUR 107.45M
- Enterprise Value
- EUR 1.15B
Share Statistics
InDex Pharmaceuticals Holding AB has 86,697,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 86,697,700
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
InDex Pharmaceuticals Holding AB’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -23.08%.
- Return on Equity (ROE)
- -0.22
- Return on Assets (ROA)
- -0.22
- Return on Invested Capital (ROIC)
- -23.08%
- Return on Capital Employed (ROCE)
- -0.23
- Revenue Per Employee
- 1.10M
- Profits Per Employee
- -94.61M
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of InDex Pharmaceuticals Holding AB is -1.08. InDex Pharmaceuticals Holding AB’s PEG ratio is 0.01.
- PE Ratio
- -1.08
- PS Ratio
- -220.99
- PB Ratio
- 0.36
- Price to FCF
- -36.36
- Price to Operating Cash Flow
- -36.36
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, InDex Pharmaceuticals Holding AB had revenue of 8.80M and earned -756.90M in profits. Earnings per share was -9.71.
- Revenue
- 8.80M
- Gross Profit
- -12.70M
- Operating Income
- -782.10M
- Pretax Income
- -757.90M
- Net Income
- -756.90M
- EBITDA
- -743.60M
- Earnings Per Share (EPS)
- -9.71
Cash Flow
In the last 12 months, operating cash flow was -31.00M and capital expenditures 3.30M, giving a free cash flow of -31.00M billion.
- Operating Cash Flow
- -31.00M
- Free Cash Flow
- -31.00M
- Free Cash Flow per Share
- -0.36
Dividends & Yields
InDex Pharmaceuticals Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.79%
- Earnings Yield
- -87.90%
Stock Price Statistics
- Beta
- 0.14
- 52-Week Price Change
- -64.59%
- 50-Day Moving Average
- 1.35
- 200-Day Moving Average
- 1.98
- Relative Strength Index (RSI)
- 35.99
- Average Volume (3m)
- 8,403
Important Dates
InDex Pharmaceuticals Holding AB upcoming earnings date is Jan 20, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Oct 15, 2026
- Next Earnings Date
- Jan 20, 2027
- Ex-Dividend Date
- ―
Financial Position
InDex Pharmaceuticals Holding AB as a current ratio of 52.31, with Debt / Equity ratio of 0.06%
- Current Ratio
- 52.31
- Quick Ratio
- 52.31
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.72
- Interest Coverage Ratio
- -57.09
Taxes
In the past 12 months, InDex Pharmaceuticals Holding AB has paid -1.00M in taxes.
- Income Tax
- -1.00M
- Effective Tax Rate
- 0.00
Enterprise Valuation
InDex Pharmaceuticals Holding AB EV to EBITDA ratio is -0.97, with an EV/FCF ratio of -27.30.
- EV to Sales
- -165.93
- EV to EBITDA
- -0.97
- EV to Free Cash Flow
- -27.30
- EV to Operating Cash Flow
- -27.30
Balance Sheet
InDex Pharmaceuticals Holding AB has EUR 265.10M in cash and marketable securities with EUR 1.60M in debt, giving a net cash position of EUR 263.50M billion.
- Cash & Marketable Securities
- EUR 265.10M
- Total Debt
- EUR 1.60M
- Net Cash
- EUR 263.50M
- Net Cash Per Share
- EUR 3.04
- Tangible Book Value Per Share
- EUR 35.91
Margins
Gross margin is 547.06%, with operating margin of 20343.14%, and net profit margin of 19127.45%.
- Gross Margin
- 547.06%
- Operating Margin
- 20343.14%
- Pretax Margin
- 18992.16%
- Net Profit Margin
- 19127.45%
- EBITDA Margin
- 17127.45%
- EBIT Margin
- 17137.25%
Analyst Forecast
The average price target for InDex Pharmaceuticals Holding AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -180.59%
- EPS Growth Forecast
- -265.58%
